Skip to main content
Top
Published in: Investigational New Drugs 4/2010

01-08-2010 | PRECLINICAL STUDIES

The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12

Authors: Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek

Published in: Investigational New Drugs | Issue 4/2010

Login to get access

Summary

In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21WAF1/CIP1 protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.
Literature
1.
go back to reference Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer–a consensus statement on standard practice. Br J Cancer 78:1404–1406PubMed Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer–a consensus statement on standard practice. Br J Cancer 78:1404–1406PubMed
2.
go back to reference Zlatanova J, Yaneva J, Leuba SH (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12:791–799PubMed Zlatanova J, Yaneva J, Leuba SH (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12:791–799PubMed
4.
go back to reference Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B (ed) Cisplatin, chemistry, and biochemistry of a leading anticancer drug, 1st edn. Helvetica Chimica Acta, Zürich, pp 111–135 Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B (ed) Cisplatin, chemistry, and biochemistry of a leading anticancer drug, 1st edn. Helvetica Chimica Acta, Zürich, pp 111–135
5.
go back to reference Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 47:761–763. doi:10.1021/jm030858+ CrossRefPubMed Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 47:761–763. doi:10.​1021/​jm030858+ CrossRefPubMed
6.
go back to reference Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12. Int J Pharm 288:123–129 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV). doi:10.1016/j.ijpharm.2004.09.020 CrossRefPubMed Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12. Int J Pharm 288:123–129 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV). doi:10.​1016/​j.​ijpharm.​2004.​09.​020 CrossRefPubMed
7.
go back to reference Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Zak F, Mistr A, Turanek J (2005) High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373–383. doi:10.1016/j.bcp.2004.09.005 CrossRefPubMed Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Zak F, Mistr A, Turanek J (2005) High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373–383. doi:10.​1016/​j.​bcp.​2004.​09.​005 CrossRefPubMed
14.
go back to reference El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174PubMed El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174PubMed
15.
go back to reference Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023. doi:10.1016/0092-8674(94) 90379-4 CrossRefPubMed Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023. doi:10.​1016/​0092-8674(94) 90379-4 CrossRefPubMed
16.
go back to reference Loignon M, Fetni R, Gordon AJ, Drobetsky EA (1997) A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 57:3390–3394PubMed Loignon M, Fetni R, Gordon AJ, Drobetsky EA (1997) A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 57:3390–3394PubMed
18.
21.
go back to reference Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW (1992) Neuromedin B is present in lung cancer cell lines. Cancer Res 52:2732s–2736sPubMed Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW (1992) Neuromedin B is present in lung cancer cell lines. Cancer Res 52:2732s–2736sPubMed
22.
go back to reference Shaulian E, Haviv I, Shaul Y, Oren M (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671–680PubMed Shaulian E, Haviv I, Shaul Y, Oren M (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671–680PubMed
23.
go back to reference Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244. doi:10.1016/0022-1759(92)90122-A CrossRefPubMed Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244. doi:10.​1016/​0022-1759(92)90122-A CrossRefPubMed
25.
go back to reference Fredersdorf S, Milne AW, Hall PA, Lu X (1996) Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 148:825–835PubMed Fredersdorf S, Milne AW, Hall PA, Lu X (1996) Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 148:825–835PubMed
29.
go back to reference Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B (2008) The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs 19:369–379. doi:10.1097/CAD.0b013e3282f7f500 CrossRefPubMed Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B (2008) The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs 19:369–379. doi:10.​1097/​CAD.​0b013e3282f7f500​ CrossRefPubMed
31.
32.
go back to reference Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A (2007) Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest New Drugs 5:435–443. doi:10.1007/s10637-007-9062-7 CrossRef Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A (2007) Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest New Drugs 5:435–443. doi:10.​1007/​s10637-007-9062-7 CrossRef
33.
go back to reference Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A (2006) Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 102:32–40. doi:10.1016/j.ygyno.2005.11.016 CrossRefPubMed Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A (2006) Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 102:32–40. doi:10.​1016/​j.​ygyno.​2005.​11.​016 CrossRefPubMed
Metadata
Title
The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12
Authors
Eva Roubalová
Veronika Kvardová
Roman Hrstka
Šárka Bořilová
Eva Michalová
Lenka Dubská
Petr Müller
Petr Sova
Bořivoj Vojtěšek
Publication date
01-08-2010
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9270-4

Other articles of this Issue 4/2010

Investigational New Drugs 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine